Articles related to PERSONALIZED MEDICINE

Tumor genomes may evolve during treatment as resistant subclones emerge under therapeutic pressure, prompting increasing use of comprehensive genomic profiling and serial ctDNA testing to inform ongoing precision oncology decisions.

Genetic testing identifies causative variants in approximately 65% to 70% of suspected inherited retinal disease cases and may shorten diagnostic delays. Advances in sequencing technologies and expanding testing access continue to shape retinal disease evaluation and counseling.

Individuals with psychiatric disorders demonstrated reduced flexibility in brain network reconfiguration across cognitive states in a transdiagnostic neuroimaging study. The findings linked dynamic brain patterns with symptom profiles but did not establish causality or clinical applicability.

ASCO released updated recommendations for recurrent ovarian cancer that reinforce platinum-based doublet therapy as the preferred approach for platinum-sensitive disease and provide guidance for platinum-resistant disease, maintenance strategies, and monitoring. Recommendations were derived from a systematic review of studies published through 2025.

A randomized noninferiority trial involving 648 men with MRI-visible prostate lesions found that cognitive fusion biopsy achieved clinically significant prostate cancer detection rates similar to software-based fusion biopsy. Subgroup analyses suggested body mass index may influence the relative performance of each approach.

A repeat PSMA PET/CT scan detected recurrent disease in more than half of prostate cancer patients whose initial scan was negative. Findings altered management in nearly half of patients, particularly those with oligometastatic recurrence.